Companies › CatalYm
1 active drug program in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Visugromab (CTL-002) GDF-15 neutralizing antibody | GDF15 | Phase 2 | Metastatic Non-Squamous Non-Small Cell Lung Cancer; Unresectable or Metastatic Hepatocellular Carcinoma; Cancer-associated Cachexia; Solid Tumor, Adult | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04725474 | Visugromab (CTL-002) | Phase 1 | Solid Tumor, Adult | Oncology | Apr 2028 |
| NCT07098988 | Visugromab (CTL-002) | Phase 2 | Metastatic Non-Squamous Non-Small Cell Lung Cancer | Oncology | Mar 2029 |
| NCT07219459 | Visugromab (CTL-002) | Phase 2 | Unresectable or Metastatic Hepatocellular Carcinoma | Oncology | Sep 2029 |
| NCT07246863 | Visugromab (CTL-002) | Phase 2 | Metastatic Non-Squamous Non-Small Cell Lung Cancer | Oncology | Oct 2029 |
| NCT07112196 | Visugromab (CTL-002) | Phase 2 | Cancer-associated Cachexia | Oncology | Dec 2029 |
Alethia Biotherapeutics Solstice Oncology CrystalGenomics Partner Therapeutics STCube
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.